Latest Commercialisation News

Proteomics International Laboratories has appointed David Morris as CEO and Managing Director, marking a strategic shift towards commercialising its Promarker® diagnostic technology. Morris brings extensive global healthcare leadership experience to lead the company’s next growth phase.

Neometals and Mineral Resources’ joint venture Reed Advanced Materials has teamed up with electrochemical leader De Nora to pilot an integrated lithium hydroxide production plant, advancing sustainable battery materials technology.

NeuroScientific Biopharmaceuticals reports encouraging clinical responses in fistulising Crohn’s disease patients treated under Australia’s Special Access Scheme, setting the stage for pivotal Phase 2 trials later this year.

AdAlta Limited has raised A$1.2 million through a strategic placement to advance its innovative PD1 armored MSLN CAR-T therapy for solid cancers, reinforcing its unique 'East to West' cellular immunotherapy approach.

Tetratherix has successfully completed the second safety review of its TetraDerm clinical trial's second cohort, showing no adverse events and confirming a strong safety profile. The trial now progresses to its final phase, targeting a growing reconstructive surgery market.

Eminence Minerals has engaged Brazilian consultancy GE21 to conduct a strategic technical review of its Campo Grande rare earth project, aiming to pave the way for a formal resource estimate and development studies.

Janus Electric has appointed Ben Hutt as CEO and Managing Director, aiming to fast-track its innovative exchangeable battery systems for heavy transport. Hutt’s extensive energy transition and capital markets experience positions the company for its next growth phase.

Zeotech Limited is set to validate its zeolite-based methane biofilter in a six-month on-site trial at a North Burnett landfill, aiming to curb emissions by over 90%. This marks a critical step from lab success to real-world application, supporting Australia’s climate goals.

Firebird Metals has commissioned its proprietary equipment for producing advanced lithium-manganese-rich cathode materials at its China pilot plant, aiming to start production in February 2026 with customer samples planned for later in the year. The project is co-funded by strategic partner Taza Metal Technologies, reducing capital risk and accelerating development.

Clinuvel Pharmaceuticals has initiated dosing in a preclinical study of its novel controlled-release injectable peptide platform, VLRX-L, aiming to enhance drug delivery for melanocortin-based therapies. Preliminary results are expected in the second half of 2026.

EBR Systems reported a doubling of WiSE System implants in Q4 FY2025 alongside the launch of key clinical studies and preliminary revenue guidance, signalling strong commercial and clinical momentum.

Imricor Medical Systems has achieved a major milestone with FDA clearance for its Vision-MR Diagnostic Catheter, paving the way for commercial sales in the US electrophysiology market.